Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia
Table 2
Operative details of CRS plus HIPEC.
(%)
Viscera resected
Appendectomy
4 (36.4)
Cholecystectomy
7 (63.6)
Splenectomy
2 (18.2)
Distal pancreatectomy
1 (9.1)
Omentectomy
4 (36.4)
Peritonectomy
5 (45.5)
Anterior parietal peritonectomy
3 (27.3)
Pelvic peritonectomy
2 (18.2)
Urinary bladder dissection
1 (9.1)
Diaphragm resection
1 (9.1)
Small bowel resection
4 (36.4)
Large bowel resection
8 (72.7)
Low anterior resection
1 (9.1)
TAH + BSO
2 (18.2)
Median enteric anastomosis (range)
1 (1–3)
CC
CC-0
7 (63.6)
CC-1
4 (36.4)
Median PCI ± SD (range)
14 ± 8.9 (3–29)
HIPEC chemotherapeutic
Cisplatin plus doxorubicin
6 (54.5)
Melphalan
4 (36.4)
Mitomycin-c
1 (9.1)
Intraoperative radiation therapy (IORT)
5 (45.5)
Median operative time ± SD (range)
8 ± 1.4 hr (6–10)
Median EBL ± SD (range)
1000 mL ± 250 (700–3850)
Intraoperative morbidity
0
Intraoperative mortality
0
SD: standard deviation; CC: cytoreduction completeness; PCI: peritoneal cancer index; HIPEC: hyperthermic intraperitoneal chemotherapy; TAH + BSO: total abdominal hysterectomy and bilateral salpingo-oophorectomy; EBL: estimated blood loss.
